Intercept Pharmaceuticals (ICPT) Trading Up 5.6%
Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) were up 5.6% during mid-day trading on Friday . The stock traded as high as $61.48 and last traded at $61.46. Approximately 682,400 shares changed hands during mid-day trading, a decline of 11% from the average daily volume of 770,037 shares. The stock had previously closed at $58.20.
Several analysts have recently issued reports on ICPT shares. BidaskClub upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 24th. Wedbush reiterated an “outperform” rating and issued a $253.00 target price on shares of Intercept Pharmaceuticals in a research note on Friday, August 25th. ValuEngine upgraded shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Wells Fargo & Company restated an “outperform” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Finally, Cantor Fitzgerald restated an “underweight” rating and set a $69.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Four investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $144.13.
The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The firm had revenue of $41.33 million for the quarter, compared to the consensus estimate of $36.95 million. During the same period in the prior year, the firm posted ($3.59) earnings per share. The company’s revenue for the quarter was up 697.9% on a year-over-year basis. analysts anticipate that Intercept Pharmaceuticals, Inc. will post -13.35 EPS for the current year.
In related news, CEO Mark Pruzanski sold 1,532 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $58.87, for a total value of $90,188.84. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold 2,566 shares of company stock worth $151,025 over the last ninety days. 9.20% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. WFG Advisors LP grew its position in Intercept Pharmaceuticals by 16.4% during the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 125 shares during the last quarter. IFP Advisors Inc grew its position in Intercept Pharmaceuticals by 128.1% during the second quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 730 shares during the last quarter. Aperio Group LLC bought a new position in Intercept Pharmaceuticals during the second quarter valued at approximately $212,000. SG Americas Securities LLC bought a new position in Intercept Pharmaceuticals during the second quarter valued at approximately $235,000. Finally, QCM Cayman Ltd. bought a new position in Intercept Pharmaceuticals during the second quarter valued at approximately $237,000. Institutional investors and hedge funds own 73.80% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.